INNOVADERM CRO IS NOW INDERO.

Pharmacovigilance (Drug Safety) Services

Pharmacovigilance services for any drug, biologic, or medical device in any indication.

Manage Safety with Expert Pharmacovigilance Capabilities

Indero’s pharmacovigilance team assesses and manages drug safety to ensure regulatory compliance and mitigate risks associated with adverse events. Here’s an overview of our key pharmacovigilance services:

  • Develop a fully compliant safety management plan along with the reporting forms and completion guidelines
  • Implement and validate Oracle Argus Safety in collaboration with the cloud host, ensuring compliance with ISO security and quality certifications, including ISO 9001, ISO 27001, ISO 27017, and ISO 27018
  • Collect and manage safety data, including triage, processing, and management of serious adverse events (SAEs), suspected unexpected serious adverse reactions (SUSARs), and other safety records
  • Writing of narratives and analysis of similar events (AOSE) as applicable
  • Migrate legacy data into Argus Safety
  • Expedited reporting to EudraVigilance (EMA), FDA, Health Canada, IRB, and other regulatory authorities
  • Maintain a case tracker for SAEs, SUSARs, pregnancy cases, overdose cases, and other applicable events
  • Generate CIOMS/MedWatch/XML reports electronically and distribute them to the sponsor or regulatory team, including cross-reports
  • Reconcile the safety database with the clinical database in collaboration with the data management team
  • Conduct safety reviews of coding at planned intervals
  • Prepare Development Safety Update Reports (DSURs)
  • Registration of IMP in XEVMPD for trials in Europe
  • Act as the Responsible Person for EudraVigilance on behalf of the Sponsors

Extensive Therapeutic Knowledge & Experience

Indero supports pharmacovigilance for dermatology, rheumatology, and a wide range of other therapeutic areas. 

SAE & SUSAR Management

When sites report SAEs or SUSARs to Indero’s pharmacovigilance unit, we respond in a timely, coordinated manner to ensure an up-to-date, compliant safety database.

  • Notify sponsor within 1 business day following data entry in safety database
  • Determine expectedness in consultation with study sponsor
  • If SUSAR, we handle submitting final CIOMS/MedWatch/XML to regulatory authorities, investigator sites, and the central or local IRB

Partner with Indero’s Pharmacovigilance Team

Indero has over 25 years of experience in meeting sponsor expectations with high quality, compliant drug safety data. Tell us about your pharmacovigilance needs today.

Pharmacovigilance Services that Accelerate Studies

Scientific discipline. Operational efficiency. Clinical development expertise. Our pharmacovigilance services provide the rigorous foundation, quality data, and expertise clinical trials need to ensure effective execution and on-time delivery.

“The expertise and motivation Indero brought to the table were pivotal to our success. From the initial synopsis development to the final stages of study conduct, the synergy between our teams was palpable and was underpinned by Indero’s strong relationships with sites, investigators, and KOLs.”

Snehal Naik, PhD

Senior Vice President,
Clinical Development

Frequently Asked Questions

How do rheumatology CROs contribute to drug development?

Rheumatology CROs, such as Indero, are essential in ensuring drug safety and regulatory compliance throughout the clinical development process. They contribute by closely monitoring adverse events (AEs), serious adverse events (SAEs), and suspected unexpected serious adverse reactions (SUSARs), particularly in chronic conditions where treatments may carry long-term risks. By using specialized safety management systems, CROs not only ensure real-time safety reporting but also help identify potential risks early, preventing delays in development. Their expertise in navigating regulatory reporting requirements ensures that safety data are communicated efficiently to regulatory bodies, facilitating smoother approval processes and ensuring patient safety at every stage of the trial.

Pharmacovigilance services are integral to maintaining drug safety and mitigating risks during clinical trials, ultimately supporting the drug development timeline. By continuously monitoring adverse events (AEs), serious adverse events (SAEs), and suspected unexpected serious adverse reactions (SUSARs), pharmacovigilance teams help identify potential risks early, allowing for timely interventions. This proactive approach ensures regulatory compliance and facilitates the submission of safety data to regulatory authorities within required timelines, helping to prevent delays in trial progression and product approval.

The key responsibilities of a pharmacovigilance team include:

  • Safety data collection and management: Gathering, processing, and maintaining comprehensive safety data from clinical trials

  • Adverse event reporting: Reporting SUSARs to regulatory bodies within required timelines

  • Risk assessment and management: Assessing potential risks related to adverse events and implementing strategies to mitigate them

  • Regulatory compliance: Ensuring that safety reporting aligns with local and international regulatory guidelines (e.g., FDA, EMA)

  • Safety reviews: Conducting ongoing safety reviews of trial data, including coding of adverse events, and providing feedback for improving safety protocols

  • Narrative writing: Writing detailed narratives for safety reports, helping to communicate the context and implications of adverse events clearly

Compliance Area Indero’s Approach
Safety Data Management Utilizing Oracle Argus Safety to ensure compliant safety data management, aligned with ISO 9001, ISO 27001, and other relevant certifications
Reporting to Regulatory Authorities Expedited reporting of SAEs, SUSARs, and other events to FDA, EMA, Health Canada, and IRBs within regulatory timelines
Regulatory Submissions Preparing and submitting accurate CIOMS/MedWatch/XML reports to meet regulatory expectations
Case Reconciliation Ensuring alignment between safety and clinical databases for consistent reporting and analysis
Compliance Audits and Reviews Conducting regular reviews and audits to ensure compliance with both internal and regulatory standards

Wherever
You’re Going,
We’re all in.

Need help with your next study? We want to learn more. Fill out the form on the right and one of our experts will be in touch.

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte près de 30 ans d’expérience dans l’industrie pharmaceutique et CRO, s’étant distingué par son leadership exceptionnel, sa vision stratégique et son innovation. L’expertise de Jeff couvre des opérations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matière de création de valeur, de gestion des partenaires et d’opérations CRO ont toujours contribué au succès dans ses fonctions précédentes. Sous la direction de Jeff, Indero continue d’étendre ses capacités, faisant progresser les connaissances médicales et les nouvelles thérapies en dermatologie et en rhumatologie.